What is the role of SC injection (Sublocade) in the treatment of opioid use disorder (OUD)?

Updated: Jun 21, 2018
  • Author: David W Dixon, DO; Chief Editor: Glen L Xiong, MD  more...
  • Print

In 2017, the FDA approved a once-monthly SC injection (Sublocade) for opioid use disorder (OUD). When injected, it forms a solid mass upon contact with body fluids from the Atrigel delivery mechanism. The drug must be administered in a healthcare setting to avoid inadvertent IV administration that could result in death. It is indicated for treatment of moderate-to-severe OUD in adults who have initiated treatment with a transmucosal buprenorphine-containing product and have been on a stable dose of transmucosal buprenorphine treatment for ≥7 days. [47]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!